WANY
CTXR icon

Wealthspire Advisors (New York)’s Citius Pharmaceuticals CTXR Stock Holding History

Wealthspire Advisors (New York)’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,580
Closed -$80K – 555
2021
Q3 		$80K Buy
+1,580
New +$79.3K ﹤0.01% 569

Other funds holding CTXR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wealthspire Advisors (New York)'s CTXR Position: Q4 2021 in Review

Wealthspire Advisors (New York) sold out of Citius Pharmaceuticals (CTXR) in Q4 2021, closing a stake of 1,580 shares — an estimated $80K sold.

Wealthspire Advisors (New York) first reported a position in CTXR in Q3 2021 and held it in 1 quarter. The position peaked at $80K in Q3 2021. 76 funds tracked by Wall St. Rank hold CTXR as of Q4 2021.

  • Wealthspire Advisors (New York) reported no remaining Citius Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 1,580 Citius Pharmaceuticals shares in Q4 2021, an estimated $80K.
  • Wealthspire Advisors (New York) first reported a position in Citius Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Citius Pharmaceuticals position peaked at $80K in Q3 2021.
  • 76 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q4 2021.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2021, filed 14 Feb 2022.